-
1دورية أكاديمية
المؤلفون: Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour
المصدر: Pharmaceuticals; Volume 13; Issue 11; Pages: 371
مصطلحات موضوعية: ALK -positive disease, ROS1 -positive disease, ALK tyrosine kinase inhibitor treatment, sequential treatment, lorlatinib
وصف الملف: application/pdf
العلاقة: Pharmacology; https://dx.doi.org/10.3390/ph13110371Test
-
2دورية أكاديمية
المؤلفون: Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour
المصدر: Pharmaceuticals, Vol 13, Iss 371, p 371 (2020)
مصطلحات موضوعية: ALK -positive disease, ROS1 -positive disease, ALK tyrosine kinase inhibitor treatment, sequential treatment, lorlatinib, Medicine, Pharmacy and materia medica, RS1-441
العلاقة: https://www.mdpi.com/1424-8247/13/11/371Test; https://doaj.org/toc/1424-8247Test; https://doaj.org/article/c5a19e6cd3264f17ba16255cddad1e6eTest
الإتاحة: https://doi.org/10.3390/ph13110371Test
https://doaj.org/article/c5a19e6cd3264f17ba16255cddad1e6eTest